Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

TSVT

2seventy bio Inc

May 02 • 04:00PM ET

4.93

Dollar change +0.33
Percentage change 7.17	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT ITOT IWC PRFZ

Index	RUT	P/E	-	EPS (ttm)	-4.41	Insider Own	7.16%	Shs Outstand	50.63M	Perf Week	14.92%
Market Cap	253.40M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	22.75%	Shs Float	47.72M	Perf Month	-1.00%
Income	-217.57M	PEG	-	EPS next Q	-0.75	Inst Own	93.28%	Short Float	13.58%	Perf Quarter	-5.01%
Sales	100.39M	P/S	2.52	EPS this Y	56.23%	Inst Trans	-1.52%	Short Ratio	5.50	Perf Half Y	102.05%
Book/sh	5.04	P/B	0.98	EPS next Y	64.93%	ROA	-35.61%	Short Interest	6.48M	Perf Year	-51.57%
Cash/sh	4.22	P/C	1.17	EPS next 5Y	-	ROE	-76.91%	52W Range	1.53 - 12.69	Perf YTD	15.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-43.57%	52W High	-61.15%	Beta	1.87
Dividend TTM	-	Quick Ratio	3.98	Sales past 5Y	73.45%	Gross Margin	72.90%	52W Low	221.17%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	3.98	EPS Y/Y TTM	41.77%	Oper. Margin	-215.87%	RSI (14)	52.73	Volatility	6.67% 8.99%
Employees	274	Debt/Eq	1.01	Sales Y/Y TTM	9.72%	Profit Margin	-216.73%	Recom	2.14	Target Price	11.80
Option/Short	Yes / Yes	LT Debt/Eq	0.96	EPS Q/Q	-84.82%	Payout	-	Rel Volume	0.48	Prev Close	4.60
Sales Surprise	-27.35%	EPS Surprise	-7.24%	Sales Q/Q	-80.98%	Earnings	Mar 05 BMO	Avg Volume	1.18M	Price	4.93
SMA20	1.89%	SMA50	-0.86%	SMA200	9.49%	Trades		Volume	568,626	Change	7.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-24	Upgrade	Leerink Partners	Market Perform → Outperform	$5 → $18
Jan-31-24	Downgrade	TD Cowen	Outperform → Market Perform
Oct-30-23	Downgrade	Leerink Partners	Outperform → Market Perform	$6
Oct-12-23	Initiated	Citigroup	Buy	$13
Sep-13-23	Downgrade	Goldman	Buy → Neutral	$5
Sep-12-23	Downgrade	Guggenheim	Buy → Neutral
Jul-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$25 → $13
Oct-31-22	Initiated	Guggenheim	Buy	$30
May-02-22	Initiated	Goldman	Buy	$26
Feb-10-22	Initiated	SVB Leerink	Outperform	$38
Jan-06-22	Initiated	Cowen	Outperform
Nov-09-21	Initiated	Canaccord Genuity	Buy	$42
Nov-08-21	Initiated	Wedbush	Outperform
Nov-08-21	Initiated	Morgan Stanley	Overweight

Show Previous Ratings

Apr-24-24 10:01AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.78%
Apr-17-24 11:02AM	2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why (Zacks)
Apr-05-24 09:05AM	U.S. FDA Approves Bristol Myers Squibb and 2seventy bios Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy (Business Wire)
Apr-01-24 07:30AM	2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron (Business Wire) +8.22%
Mar-20-24 05:04PM	2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors (Business Wire)
06:27PM	Loading…
Mar-15-24 06:27PM	FDA Advisory Committee Votes in Favor of Bristol Myers Squibbs and 2seventy bios Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy (Business Wire)
Mar-07-24 09:10AM	2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.11%
Mar-05-24 07:53AM	TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +6.83%
07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress (Business Wire)
Mar-04-24 08:56AM	Should You Buy 2seventy bio (TSVT) Ahead of Earnings? (Zacks)
Mar-01-24 07:00AM	2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences (Business Wire) +8.46%
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile) +8.36%
Feb-05-24 04:05PM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire) +7.62%
06:59AM	Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study (Business Wire)
Feb-01-24 08:27AM	2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains? (Zacks)
11:11AM	Loading…
Jan-31-24 11:11AM	2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up (Zacks) +28.18%
Jan-30-24 07:01AM	2seventy bio Announces New Strategic Path Forward (Business Wire) +14.90%
Jan-12-24 12:00PM	All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy (Zacks)
Dec-11-23 07:30PM	Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 (Business Wire)
07:00AM	2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel) (Business Wire)
Dec-06-23 02:00PM	2seventy bio Reiterates Commitment to Maximizing Shareholder Value (Business Wire) +9.30%
Nov-20-23 12:02PM	Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug (Investopedia) -18.31%
06:59AM	Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma (Business Wire)
Nov-14-23 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-10-23 07:00AM	2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023 (Business Wire)
Sep-12-23 07:00AM	2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway (Business Wire) -5.02%
06:55AM	2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies (Business Wire)
Sep-06-23 07:00AM	2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-24-23 09:00PM	CFO Baird William D III Sells 7,031 Shares of 2seventy bio Inc (TSVT) (GuruFocus.com)
Aug-14-23 07:00AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
07:00AM	Loading…
Aug-08-23 07:00AM	2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023 (Business Wire)
Aug-01-23 04:15PM	2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference (Business Wire) -8.56%
Jun-14-23 07:00AM	2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia (Business Wire) -8.98%
Jun-07-23 07:00AM	2seventy bio to Participate in Upcoming Investor Conference (Business Wire)
May-19-23 06:00AM	2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (Business Wire)
May-17-23 07:17AM	2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio (Business Wire)
May-11-23 12:37PM	2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 (Business Wire)
May-03-23 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire)
May-02-23 04:37PM	2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting (Business Wire)
10:00AM	Billionaire Ken Griffin Doubles Down on These 2 Strong Buy Stocks Heres Why You Might Want to Follow in His Footsteps (TipRanks)
May-01-23 07:00AM	2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program (Business Wire) +8.31%
Apr-28-23 08:30AM	2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire) +5.78%
Apr-17-23 06:59AM	Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Mar-16-23 04:05PM	2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress (Business Wire)
Mar-08-23 08:30AM	2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors (Business Wire)
Mar-03-23 07:00AM	2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference (Business Wire)
Mar-01-23 09:00AM	Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer (PR Newswire) -18.38%
Feb-28-23 09:00PM	2seventy bio Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
04:01PM	2seventy bio Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-10-23 11:13AM	Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study (Business Wire)
Feb-01-23 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jan-18-23 11:35AM	Medigene Receives $3 Million Milestone Payment from 2seventy bio (GlobeNewswire)
Jan-09-23 08:00AM	2seventy bio Provides Company Outlook for 2023 (Business Wire)
Jan-06-23 09:11AM	2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors (Business Wire)
Nov-07-22 04:05PM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-03-22 09:06AM	2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-27-22 07:00AM	2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies (Business Wire)
Sep-07-22 07:00AM	2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients (Business Wire) +5.76%
Aug-31-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-22 06:23AM	2seventy bio, Inc. (NASDAQ:TSVT) Analysts Just Slashed This Year's Revenue Estimates By 12% (Simply Wall St.)
Aug-10-22 06:50AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
06:45AM	Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma (Business Wire)
Aug-04-22 07:02AM	Will 2seventy bio (NASDAQ:TSVT) Spend Its Cash Wisely? (Simply Wall St.)
Aug-03-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-04-22 03:30PM	A 2seventy bio, Inc. (NASDAQ:TSVT) insider increased their holdings by 251% last year (Simply Wall St.)
Jun-06-22 07:30AM	2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference (Business Wire)
May-12-22 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire)
May-04-22 09:10PM	Goldman Sachs Sees These 2 Strong Buy Stocks Skyrocketing Over 70% (TipRanks) +5.65%
Apr-08-22 04:15PM	2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting (Business Wire)
Apr-07-22 07:30AM	2seventy bio to Participate in CG Horizons in Oncology Virtual Conference (Business Wire)
Mar-22-22 07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress (Business Wire) +5.28%
Mar-16-22 08:41AM	2seventy bio Secures $170 Million in Private Placement Equity Financing (Business Wire) +14.59%
Feb-14-22 07:30AM	2seventy bio Announces Key Management Appointments (Business Wire)
07:00AM	2seventy bio to Participate in Upcoming Healthcare Conferences (Business Wire)
Feb-11-22 09:58AM	Do Institutions Own 2seventy bio, Inc. (NASDAQ:TSVT) Shares? (Simply Wall St.) -5.84%
Feb-03-22 01:38PM	Virginia Retirement Systems Et Al Buys Wolfspeed Inc, Orion Office REIT Inc, Kyndryl Holdings ... (GuruFocus.com)
Jan-26-22 08:00AM	Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer (GlobeNewswire) -9.53%
Jan-11-22 07:00AM	2seventy bio Shares Key Milestones and Business Updates for 2022 (Business Wire)
Jan-06-22 07:00AM	2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach (Business Wire) +10.22%
Dec-13-21 06:15PM	2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting (Business Wire) +8.26%
Dec-01-21 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-15-21 10:43AM	Morgan Stanley: These 3 Strong Buy Stocks Could Surge at Least 60% (TipRanks)
Nov-10-21 04:30PM	2seventy bio to Present at the 5th Annual Cowen IO Next Summit (Business Wire) -5.08%

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Capital, LLC	Director	Mar 26 '24	Buy	5.10	40,000	203,992	2,000,000	Mar 28 08:29 PM
Casdin Capital, LLC	Director	Mar 25 '24	Buy	5.07	330,000	1,673,991	1,960,000	Mar 25 09:44 PM
Casdin Capital, LLC	Director	Mar 22 '24	Buy	5.12	147,377	754,069	1,630,000	Mar 25 09:44 PM
Casdin Capital, LLC	Director	Mar 21 '24	Buy	4.90	300,000	1,470,990	1,482,623	Mar 25 09:44 PM
Leschly Nick	President and CEO	Jan 05 '24	Sale	3.75	1,554	5,833	1,085,476	Jan 09 04:08 PM
Baird William D III	Chief Operating Officer	Jan 05 '24	Sale	3.75	1,380	5,180	161,335	Jan 09 04:09 PM
Gregory Philip D	Chief Scientific Officer	Jan 05 '24	Sale	3.75	795	2,984	230,842	Jan 09 04:09 PM
Leschly Nick	President and CEO	Jan 03 '24	Sale	3.87	72,312	279,739	1,087,030	Jan 05 04:30 PM
Baird William D III	Chief Operating Officer	Jan 03 '24	Sale	3.87	33,651	130,179	162,715	Jan 05 04:29 PM
Gregory Philip D	Chief Scientific Officer	Jan 03 '24	Sale	3.87	25,613	99,084	231,637	Jan 05 04:30 PM
Leschly Nick	President and CEO	Aug 22 '23	Sale	5.49	9,312	51,090	1,159,342	Aug 24 05:04 PM
Baird William D III	Chief Financial Officer	Aug 22 '23	Sale	5.49	7,031	38,576	196,366	Aug 24 05:04 PM
Gregory Philip D	Chief Scientific Officer	Aug 22 '23	Sale	5.49	6,159	33,791	257,250	Aug 24 05:04 PM
Kynam Capital Management, LP	10% Owner	Aug 10 '23	Buy	5.92	515,414	3,049,287	5,953,825	Aug 14 08:51 PM
Kynam Global Healthcare Master	10% Owner	Aug 10 '23	Buy	5.92	515,414	3,049,287	5,953,825	Aug 16 07:11 PM
Kynam Global Healthcare Master	10% Owner	Aug 10 '23	Buy	5.96	86,414	515,027	5,142,111	Aug 16 07:11 PM
Kynam Capital Management, LP	10% Owner	Aug 10 '23	Buy	5.96	86,414	515,027	5,142,111	Aug 14 08:51 PM
Leschly Nick	President and CEO	Aug 03 '23	Sale	6.13	9,060	55,499	1,168,654	Aug 07 04:07 PM
Baird William D III	Chief Financial Officer	Aug 03 '23	Sale	6.13	6,906	42,304	203,397	Aug 07 04:06 PM
Gregory Philip D	Chief Scientific Officer	Aug 03 '23	Sale	6.13	3,966	24,295	263,409	Aug 07 04:06 PM

Open in Screener

BLUE

Bluebird bio Inc

May 02 • 04:00PM ET

0.9033

Dollar change -0.0060
Percentage change -0.66	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN IBB VTWO DFAT IWC ITOT DFAC

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	1.51%	Shs Outstand	192.74M	Perf Week	-1.01%
Market Cap	174.10M	Forward P/E	-	EPS next Y	-0.89	Insider Trans	-1.31%	Shs Float	189.83M	Perf Month	-23.45%
Income	-91.17M	PEG	-	EPS next Q	-0.44	Inst Own	61.85%	Short Float	17.18%	Perf Quarter	-9.55%
Sales	21.73M	P/S	8.01	EPS this Y	7.58%	Inst Trans	7.50%	Short Ratio	3.91	Perf Half Y	-69.38%
Book/sh	2.08	P/B	0.43	EPS next Y	45.17%	ROA	-16.08%	Short Interest	32.62M	Perf Year	-78.08%
Cash/sh	0.95	P/C	0.95	EPS next 5Y	45.80%	ROE	-47.81%	52W Range	0.86 - 5.53	Perf YTD	-34.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-20.06%	52W High	-83.67%	Beta	0.81
Dividend TTM	-	Quick Ratio	1.42	Sales past 5Y	120.04%	Gross Margin	-15.86%	52W Low	4.82%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.55	EPS Y/Y TTM	87.79%	Oper. Margin	-1523.91%	RSI (14)	35.63	Volatility	7.67% 8.47%
Employees	-	Debt/Eq	1.36	Sales Y/Y TTM	322.60%	Profit Margin	-419.62%	Recom	2.79	Target Price	3.89
Option/Short	Yes / Yes	LT Debt/Eq	1.04	EPS Q/Q	29.93%	Payout	-	Rel Volume	0.82	Prev Close	0.91
Sales Surprise	-53.53%	EPS Surprise	5.25%	Sales Q/Q	17353.52%	Earnings	Mar 26 BMO	Avg Volume	8.35M	Price	0.90
SMA20	-12.68%	SMA50	-27.33%	SMA200	-62.52%	Trades		Volume	6,844,762	Change	-0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-23	Downgrade	HSBC Securities	Hold → Reduce
Dec-08-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$3 → $7
Oct-17-23	Initiated	Cantor Fitzgerald	Neutral
Sep-06-23	Initiated	HSBC Securities	Buy	$4.21
Jul-19-23	Upgrade	BofA Securities	Neutral → Buy	$6 → $10
Jun-01-23	Upgrade	Barclays	Equal Weight → Overweight	$7 → $8
Apr-28-23	Initiated	JP Morgan	Overweight	$7
Mar-07-23	Initiated	Robert W. Baird	Outperform	$10
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform	$8
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight	$4
Nov-08-21	Reiterated	Wells Fargo	Equal Weight	$25 → $16
Nov-08-21	Reiterated	Wedbush	Neutral	$22 → $11
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform	$26 → $14
Nov-08-21	Reiterated	Canaccord Genuity	Hold	$20 → $15
Nov-08-21	Reiterated	Barclays	Equal Weight	$20 → $13
Nov-08-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$11
Nov-08-21	Downgrade	Goldman	Neutral → Sell	$23 → $10
Aug-10-21	Resumed	William Blair	Mkt Perform

Show Previous Ratings

Apr-26-24 04:43PM	bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report (MT Newswires)
04:05PM	bluebird bio Announces Receipt of Expected Notice from Nasdaq (Business Wire)
Apr-16-24 02:05PM	bluebird (BLUE) Underperforms Industry YTD Amid Challenges (Zacks)
Apr-15-24 08:15AM	Is Bluebird Bio Stock a Buy? (Motley Fool) -6.36%
Apr-13-24 04:22PM	Better Buy: Bluebird Bio Vs. Novavax (Motley Fool)
08:30AM	Loading…
Apr-11-24 08:30AM	Is This Beaten-Down Stock a Good Acquisition Target? (Motley Fool)
08:00AM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 11:33AM	bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:20AM	Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-27-24 11:37AM	bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates (Zacks) +13.75%
10:00AM	Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline (Zacks)
Mar-26-24 07:01AM	bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -11.76%
Mar-25-24 04:05PM	bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call (Business Wire)
Mar-19-24 07:44AM	bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up (Zacks)
Mar-18-24 06:05PM	Why Bluebird Bio Stock Flew Higher Than the Market Today (Motley Fool)
08:00AM	Loading…
08:00AM	bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital (Business Wire)
Mar-13-24 07:50AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Mar-11-24 08:00AM	bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy (Business Wire) -7.33%
Mar-05-24 06:56PM	Why Bluebird Bio Stock Dived Into the Red on Tuesday (Motley Fool) -9.15%
Jan-27-24 07:28AM	If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today (Motley Fool)
05:27AM	5 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-10-24 06:55AM	2 Red Flags for Bluebird Bio Stock (Motley Fool)
Jan-08-24 08:00AM	bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook (Business Wire)
Jan-04-24 03:32PM	Bluebirds Plans to Win in Sickle Cell Come Into Focus (The Wall Street Journal) +5.84%
Jan-03-24 07:15AM	Better Risky Investment: Bluebird Bio vs. Shiba Inu (Motley Fool) -6.80%
Jan-02-24 08:00AM	bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.52%
Dec-26-23 08:00AM	Should You Invest in Bluebird Bio Right Now? (Motley Fool)
Dec-24-23 07:39AM	If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today (Motley Fool)
Dec-23-23 07:30AM	1 Green Flag and 1 Red Flag for Bluebird Bio Stock (Motley Fool)
Dec-22-23 08:45AM	3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 (Motley Fool)
02:23PM	Loading…
Dec-20-23 02:23PM	Bluebird Bio Stock Plunges (Barrons.com) -45.68%
01:54PM	Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Heres Why. (Barrons.com)
Dec-19-23 09:41PM	bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (Business Wire) -20.33%
Dec-18-23 04:01PM	bluebird bio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire) -6.73%
Dec-15-23 11:14AM	Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock? (Motley Fool)
Dec-11-23 05:43AM	Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? (Motley Fool) +7.34%
Dec-10-23 12:02PM	Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-09-23 11:31AM	Long-term Follow-up Data From bluebirds Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events (Business Wire)
Dec-08-23 01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal) -40.54%
01:01PM	bluebird bio Details Plans for the Commercial Launch of LYFGENIA Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
12:35PM	bluebird bio Announces FDA Approval of LYFGENIA (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
Dec-07-23 11:30AM	Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Dec-01-23 07:41AM	bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How (Zacks) +11.52%
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-08-23 03:39PM	bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.91%
Nov-07-23 05:18PM	Why Bluebird Bio Stock Soared 7% Higher on Tuesday (Motley Fool) +7.27%
08:00AM	Bluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ... (GuruFocus.com)
07:46AM	Bluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates (RTT News)
07:27AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Nov-04-23 08:45AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
Nov-02-23 09:37AM	bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-30-23 08:00AM	bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million (Business Wire)
Oct-24-23 08:00AM	bluebird bio to Host Third Quarter 2023 Financial Results Conference Call (Business Wire)
Oct-17-23 09:47AM	Dollar Tree upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly)
Sep-29-23 09:00AM	Where Will Bluebird Bio Be in 1 Year? (Motley Fool)
Sep-20-23 07:21AM	Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
Sep-12-23 07:00AM	More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics (Motley Fool)
05:14AM	2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street (Motley Fool)
Sep-07-23 11:30AM	Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue? (Zacks) -7.11%
Sep-05-23 04:05PM	bluebird bio Announces September Investor Events (Business Wire)
Aug-29-23 05:25AM	Is Bluebird Bio a Bargain Buy in September? (Motley Fool)
Aug-28-23 08:30AM	Wall Street Thinks This Tiny Biotech Company Could Soar Soon (Motley Fool)
Aug-24-23 10:15AM	1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
Aug-16-23 07:00AM	bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease (Business Wire)
Aug-08-23 08:25AM	Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.06%
07:18AM	Bluebird: Q2 Earnings Snapshot (AP Finance)
07:00AM	bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
07:00AM	2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now (Motley Fool)
Aug-05-23 09:40AM	1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street (Motley Fool)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) -5.81%
Jul-25-23 08:00AM	bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update (Business Wire)
Jul-22-23 06:14AM	3 Small-Cap Stocks That Could Be Big-Time Winners (Motley Fool)
Jul-20-23 01:14AM	4 big analyst picks: AMD called a 'Top Pick' at Wolfe; Cisco upped at JPMorgan (Investing.com)
Jul-19-23 12:36PM	Why Bluebird Bio Stock Is Taking Flight Today (Motley Fool) +16.51%
Jun-30-23 10:15AM	Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street (Motley Fool)
Jun-29-23 09:53AM	This 1 Problem Could Sink at Least 4 Gene-Editing Stocks (Motley Fool) -5.01%
07:45AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Jun-21-23 07:00AM	bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Jun-15-23 10:00AM	2 Short-Squeeze Candidates That Could Go Parabolic (Motley Fool)
Jun-08-23 11:30AM	Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 02:09AM	4 big analyst picks: Avis Budget zooms higher on Deutsche upgrade (Investing.com) +5.67%
May-10-23 07:57AM	Will bluebird bio (NASDAQ:BLUE) Spend Its Cash Wisely? (Simply Wall St.)
May-09-23 07:10AM	Bluebird: Q1 Earnings Snapshot (AP Finance) +12.64%
07:00AM	bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Apr-27-23 04:05PM	bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events (Business Wire)
Apr-24-23 03:49PM	With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 (Benzinga)
07:30AM	bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Apr-13-23 02:17PM	$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis (Benzinga) +17.20%
Apr-06-23 10:15AM	Should Investors Buy the Dip With Bluebird Bio Stock? (Motley Fool)
08:00AM	What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
06:30AM	Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio (Motley Fool)
Apr-02-23 09:15AM	1 Small-Cap Stock That Could Soar in 2023 (Motley Fool)
Mar-30-23 01:54PM	Why Bluebird Bio Stock Is Sinking This Week (Motley Fool)
Mar-29-23 08:15AM	Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -24.54%
07:00AM	bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress (Business Wire)
Feb-24-23 10:00AM	Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Obenshain Andrew	President and CEO	Mar 04 '24	Sale	1.53	6,095	9,311	279,998	Mar 05 05:40 PM
Klima Thomas J	See Remarks	Mar 04 '24	Sale	1.53	4,573	6,986	124,840	Mar 05 05:39 PM
Colvin Richard A	Chief Medical Officer	Mar 01 '24	Sale	1.53	6,770	10,342	118,368	Mar 05 05:40 PM
Vittiglio Joseph	Chief Business & Legal Officer	Feb 05 '24	Sale	0.90	5,217	4,708	44,783	Feb 06 04:07 PM
Klima Thomas J	See Remarks	Feb 05 '24	Sale	0.90	2,714	2,449	129,413	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Feb 05 '24	Sale	0.90	1,879	1,696	286,093	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Jan 05 '24	Sale	1.43	3,162	4,520	287,972	Jan 09 04:05 PM
Colvin Richard A	Chief Medical Officer	Jan 05 '24	Sale	1.42	597	845	125,138	Jan 09 04:05 PM
Krawtschuk Christopher	Chief Financial Officer	Dec 06 '23	Sale	4.52	4,526	20,437	45,474	Dec 08 04:42 PM
Obenshain Andrew	President and CEO	Nov 03 '23	Sale	3.17	807	2,555	291,134	Nov 03 04:10 PM
Colvin Richard A	Chief Medical Officer	Nov 02 '23	Sale	2.98	2,343	6,975	125,735	Nov 03 04:10 PM
Klima Thomas J	See Remarks	Sep 05 '23	Sale	3.79	922	3,493	132,127	Sep 06 04:30 PM
Obenshain Andrew	President and CEO	Aug 10 '23	Sale	3.54	16,929	59,956	291,941	Aug 10 05:00 PM
Klima Thomas J	See Remarks	Jun 02 '23	Sale	3.50	4,130	14,451	133,049	Jun 06 04:06 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

TSVT

2seventy bio Inc

BLUE

Bluebird bio Inc

Upgrade your FINVIZ experience